Loading…
← CockpitCompetitor Analysis › 6998.HK Edding Genor Group Holdings LimitedOpen in the cockpit ↗

Edding Genor Group Holdings Limited6998.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Biotechnology
Momentum neutral 48
Mkt cap
$410M
US dollars, full cap
Free float
37%
of shares outstanding
$/day
$109,135
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+7.5 pp
WACC 8.9%
Hurdle
-213 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · HKDHK$1.57
1D-1.9%
1W+1.0%
1M-5.4%
3M-1.3%
6M-34.6%
YTD-47.7%
1Y-47.7%
ATR %3.5%
52w lowhigh59.7% off high

What Edding Genor does

Employees: 1,545

Edding Genor at a glance

Size Edding Genor (6998.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $410M, the 798th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$1.57 on 18 Nov 2026.

Performance Over six months the shares fell 34.6%, against -22.0% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 4th lowest of 21 in its peer set.

Growth Revenue grew 1,417.7% over the last twelve months (peer median +5.9%); the operating margin is 26.2% (peer median -7.2%).

Valuation It trades at 1.0× enterprise value to sales against a peer median of 5.6× (cheapest of 17).

Price implies For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +197%, so the hurdle is -213 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 7.5 points above its cost of capital (8.9% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

70809010021 May 202621 Aug 202618 Nov 2026Peer median 776998.HK 72
Six months, rebased to 100: Edding Genor against the median of its 20 peers (local-currency closes).

Edding Genor financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueHK$3.68BHK$2.70BHK$2.76BHK$0HK$18.5M
Revenue growth—-2%—-100%—
Gross profitHK$2.59BHK$1.76BHK$1.78B-HK$85.0M-HK$45.0M
EBITDAn/aHK$954MHK$924M-HK$687M-HK$852M
Net incomeHK$421MHK$433MHK$421M-HK$745M-HK$849M
Free cash flowHK$616MHK$236MHK$688M-HK$471M-HK$686M
Capital expenditureHK$61.4MHK$51.7MHK$218MHK$1.14MHK$15.1M
Total debtn/aHK$1.66BHK$2.16BHK$7.88MHK$32.1M

Quarterly statements and history in the cockpit →

Edding Genor competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%-10%0%3378688238EPRX6881631167456160CADL4768306880986883172480654730068367122509PRTA688687PNV17893009666998.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Edding Genor is the large dot.

Fundamentals: revenue growth against valuation

0%+500%+1,000%+1,500%0×500×688238688163116745616047683025096998.HKRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Edding Genor is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%0%100%200%11676883176712688687PNV17896998.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Edding Genor is the large dot.

Edding Genor competitors and peer comparison

How Edding Genor compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Edding Genor against its 20 peers (data as of 18 Nov 2026)
Measure6998.HKPeer medianRank in peer set
1-month return-5.4%-13.4%5th highest of 21
6-month return-34.6%-22.0%4th lowest of 21
Distance from 52-week high-59.7%-40.6%4th lowest of 21
Revenue growth (TTM)+1,417.7%+5.9%highest of 17
Operating margin26.2%-7.2%4th highest of 17
EV / Sales1.0×5.6×cheapest of 17
Growth the price implies (Req g, 7 yrs)-15.3%4.0%3rd least demanding of 8
Growth delivered (Del g)+197.3%+4.7%highest of 7
Hurdle (Req g minus delivered)-212.7 pp+15.8 ppleast demanding of 7
ROIC minus cost of capital+7.5 pp-8.4 pp3rd highest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Edding Genor 6998.HKHong Kong$410M-35%+1,418%26%1.0×-15.3%+197.3%
Hanx Biopharmaceuticals (Wuhan) 3378.HKHong Kong$409M-24%n/an/an/an/an/a
Shanghai Obio Technology (Group) 688238.SSChina$414M-5%+20%-79%10.3×n/an/a
Eupraxia Pharmaceuticals EPRX.TOCanada$416M+1%n/an/an/an/an/a
Shanghai Serum Bio-Technology 688163.SSChina$416M-34%-1%26%10.6×n/an/a
Jacobio Pharmaceuticals 1167.HKHong Kong$404M-24%+286%68%1.9×-18.8%-36.1%
G2GBIO 456160.KSSouth Korea$416M-53%-45%-2,884%908.6×n/an/a
Candel Therapeutics CADLUnited States$417M-31%n/an/an/an/an/a
Rznomics 476830.KSSouth Korea$418M-76%-65%-1,112%215.1×n/an/a
Shanghai Shen Lian Biomedical 688098.SSChina$402M-22%-17%-16%10.9×n/an/a
Shanghai ZJ Bio-Tech 688317.SSChina$422M-22%-10%-72%2.9×4.0%-62.3%
Beijing Luzhu Biotechnology 2480.HKHong Kong$396M-33%n/an/an/an/an/a
Medigen Vaccine Biologics 6547.TWOTaiwan$424M-8%+44%-5%14.6×n/an/a
Wuhan Hiteck Biological Pharma 300683.SZChina$395M-41%-30%-27%5.2×n/an/a
Ever Supreme Bio Technology 6712.TWOTaiwan$427M+11%+13%47%12.3×5.3%+70.5%
Qyuns Therapeutics 2509.HKHong Kong$428M-11%+230%56%2.6×-19.5%n/a
Prothena PRTAUnited States$429M-11%+347%-73%3.1×n/an/a
Beijing Kawin Technology Share-Holding 688687.SSChina$391M-20%+6%-2%1.7×36.6%+8.9%
Polynovo PNV.AXAustralia$388M-34%+13%5%3.9×51.9%+37.6%
Scinopharm Taiwan 1789.TWTaiwan$435M-2%-5%-4%4.0×2.1%+0.5%
Hubei Goto Biopharm 300966.SZChina$386M-16%+6%-10%6.0×n/an/a

Questions

Which companies are Edding Genor's closest peers?
The cockpit's peer set: Hanx Biopharmaceuticals (Wuhan) (3378.HK), Shanghai Obio Technology (Group) (688238.SS), Eupraxia Pharmaceuticals (EPRX.TO), Shanghai Serum Bio-Technology (688163.SS), Jacobio Pharmaceuticals (1167.HK), G2GBIO (456160.KS), Candel Therapeutics (CADL), Rznomics (476830.KS).
Is Edding Genor expensive compared with its peers?
On ev / sales it trades at 1.0× against a peer median of 5.6×, cheapest of 17 in its peer set. For today's price to make sense, revenue must grow about -15% a year for seven years (Req g). Recent delivered growth is +197%, so the hurdle is -213 pp: the price already allows for a slowdown.
How has Edding Genor stock performed?
Over six months to 18 Nov 2026 the shares returned -34.6% against -22.0% for the median peer; over one year -47.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.